Anthony J. Polverino
Directeur/Membre du Conseil chez BRAINSTORM CELL THERAPEUTICS INC.
Fortune : 13 811 $ au 30/04/2024
Postes actifs de Anthony J. Polverino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Directeur/Membre du Conseil | 05/02/2018 | - |
| Independent Dir/Board Member | 05/02/2018 | - |
Historique de carrière de Anthony J. Polverino
Anciens postes connus de Anthony J. Polverino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Directeur Technique/Scientifique/R&D | 20/09/2018 | 19/01/2022 |
| KITE PHARMA INC | Directeur Technique/Scientifique/R&D | 01/01/2015 | 01/01/2018 |
| AMGEN INC. | Corporate Officer/Principal | - | - |
Formation de Anthony J. Polverino
| University of Adelaide | Undergraduate Degree |
| Flinders University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Australie | 3 |
| Canada | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
- Bourse
- Insiders
- Anthony J. Polverino
- Expérience
